1834 Investment Advisors’s CorMedix CRMD Stock Holding History

1834 Investment Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-200	Closed	-$1K	–	411
2019 Q4	$1K	Buy	+200	New	+$1.22K	﹤0.01%	441

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

1834 Investment Advisors's CRMD Position: Q1 2020 in Review

1834 Investment Advisors sold out of CorMedix (CRMD) in Q1 2020, closing a stake of 200 shares — an estimated $1K sold.

1834 Investment Advisors first reported a position in CRMD in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 59 funds tracked by Wall St. Rank hold CRMD as of Q1 2020.

1834 Investment Advisors reported no remaining CorMedix position as of Q1 2020 after selling out during the quarter.
1834 Investment Advisors sold 200 CorMedix shares in Q1 2020, an estimated $1K.
1834 Investment Advisors first reported a position in CorMedix in Q4 2019 and held it in 1 quarter.
1834 Investment Advisors's CorMedix position peaked at $1K in Q4 2019.
59 funds tracked by Wall St. Rank held CorMedix as of Q1 2020.

Based on 1834 Investment Advisors's 13F filing for Q1 2020, filed 15 May 2020.